It also provided therapeutic efficacy in the bleomycin-induced PF model at the same dose with a lung exposure of ~10 μM, which completely attenuated both bleomycin-induced iNOS activity and CB1R activation (2, 3). The gene discussed is NOS2; the disease is pemphigus foliaceus.